Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy

Xiamen Amoytop Biotech

Status: Completed

Conditions: Hepatitis B

Treatments: Drug: Peginterferon Alfa-2B; Drug: Peginterferon Alfa-2A

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT03181113

TB1510IFN

Details and patient eligibility

About

In this cohort study, patients with chronic hepatitis B who prior participated in TB1211IFN study and received at least 39 doses of peginterferon alfa will be enrolled. HBsAg/anti-HBs level, HBeAg/anti-HBe level, Serum HBV DNA load and alanine transaminase level will be test every year from the second year to the fifth year after the ending of peginterferon alfa treatment, and long-term benefit of interferon treatment will be evaluated.

Enrollment: 473 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Understand and sign the informed consent form.
• Participated in NCT01760122 study (TB1211IFN) and has received at least 39 doses of peginterferon.

Exclusion criteria

• Conditions which in the opinion of the investigator should be precluded from the study(e.g., poor compliance).

Trial design

473 participants in 2 patient groups

peginterferon alfa 2b

Treatment:

Drug: Peginterferon Alfa-2B

peginterferon alfa 2a

Treatment:

Drug: Peginterferon Alfa-2A